



PRESS RELEASE

APPROVAL OF THE CORPORATE EVENTS CALENDAR FOR 2018

Capua (CE), 21 December 2017 – The Board of Directors of Pierrel S.p.A., meeting today, has approved pursuant to Article 2.6.2 (Information requirements) of the Regulations of the Market that is organised and managed by Borsa Italiana S.p.A. – decided on 10 September 2009 and approved by the CONSOB with its decision no. 17026 of 7 October 2009, as subsequently revised and updated – the calendar of corporate events of Pierrel S.p.A. for 2018, as summarised in the following table.

Date	Event
Week of 14-21 February 2018 (date to be decided)	Board of Directors meeting to approve the draft financial statements for the year ended 31 December 2017
Week of 14-18 May 2018 (date to be decided)	Board of Directors meeting to approve on a voluntary basis the interim management report for the period ended 31 March 2018 and to renew the corporate positions
Week of 26-31 March 2018 (date to be decided)	General Meeting of shareholders to approve the financial statements for the year ended December 2017
Week of 2-8 August 2018 (date to be decided)	Board of Directors meeting to approve the abbreviated half-yearly consolidated financial statements at 30 June 2018
Week of 8-15 November 2018 (date to be decided)	Board of Directors meeting to approve on a voluntary basis the interim management report for the period ended 30 September 2018

The precise date of Directors and shareholders meetings, as well as possible changes to the above, will be communicated to the regulatory authorities and the public in the timeframe and in the manner required by law and applicable regulations.

* * *

Pierrel S.p.A. specialises in the manufacture of pharmaceutical specialty products (Contract Manufacturing Division) and the development, registration and licensing of new drugs and medical devices (Pharma Division).

The Pierrel Group is listed on the MTA exchange organised and managed by Borsa Italiana, and has over 60 years' experience in the pharmaceutical sector, as one of Europe's leading producers of local and dental anaesthetics.

Pierrel owns a production unit in Capua, near Naples, Italy, which has been authorised by the European Medicines Agency (EMA) and the Food and Drug Administration (FDA) for the aseptic production of injectable medicines.



The subsidiary Pierrel Pharma S.r.l. with sole shareholder has registered and distributes the Orabloc® dental anaesthetic in Canada, the US, Russia and Europe. The registered office of Pierrel S.p.A. is in Capua (CE), Italy

For further information:

Pierrel S.p.A.

Investor Relations

Fulvio Citaredo

E-mail: investor.relations@pierrelgroup.com

tel. +39 0823 626 111

fax +39 0823 626 228

Global Consult S.r.l.

Media Relations

Rossana Del Forno

E-mail: areacomunicazione@globalconsultsrl.com

tel. +39 333 6178665